Vermeer 1996.
Methods | RCT Study aim clearly defined: yes Blinded assessor of primary outcome: not stated Double blind study:yes Participants comparable at baseline for age: yes Sex: yes Duration of complaint: yes Inclusion and exclusion criteria specified: yes Interventions well described: yes Assessment of compliance: not stated Intention to treat analysis: not stated A Priori sample size calculation: not stated Fungi identified: yes Distribution of species between groups: no Adverse events reported: no Number of drop outs stated: no | |
Participants | Total evaluable sample size: 191 Treatment setting: Department of Dermatology (hospital) | |
Interventions | a. Terbinafine cream Duration: one week plus one week Placebo Frequency: b. Miconazole cream Duration: four weeks Frequency: | |
Outcomes | Primary outcome: cure Secondary Outcomes: Signs and symptoms ‐ itching, erythema, scaling, vesiculation | |
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |